Why the study?
Does the CYP4F2 rs3093135 TT variant alter platelet aggregation and bleeding risk in patients on ticagrelor or clopidogrel after PCI?
Does the CYP4F2 rs3093135 TT variant alter platelet aggregation and bleeding risk in patients on ticagrelor or clopidogrel after PCI?
The CYP4F2 rs3093135 TT variant is associated with increased antiplatelet effect and higher risk of nonprocedural bleeding in patients receiving ticagrelor after PCI.
Genotyping may identify DAPT response variability post-PCI; leaves open whether it improves outcomes in practice.
Aim: To determine clinically significant factors which may alter the effect of dual antiplatelet therapy with aspirin and ticagrelor or clopidogrel in patients who had undergone percutaneous coronary intervention and stent implantation. Materials & methods: The study included 378 patients. All the patients had undergone percutaneous coronary intervention and stent implantation. Platelet aggregation and genotyping for CYP2C19 *2 (rs4244285) and CYP4F2 (rs2108622, rs1558139, rs3093135 and rs2074902) was performed. Results: Significantly lower platelet aggregation values (%agr) were detected in ticagrelor users who carried CYP4F2 rs3093135 TT variant (14.67 ± 5.07%agr) versus AA (22.88 ± 6.30%agr), p = 0.0004, or AT (20.56 ± 6.51%agr), p = 0.0126. Conclusion: Results of the current study showed that CYP4F2 rs3093135 TT variant carriers had a higher antiplatelet effect of ticagrelor, and more frequently had nonprocedural bleeding during ticagrelor therapy, as compared with AA and AT variant carriers.
No takes yet. Share an insight, caveat, or question.
Tatarūnas et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: